| 000 | 01739 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250513201123.0 | ||
| 264 | 0 | _c20000201 | |
| 008 | 200002s 0 0 eng d | ||
| 022 | _a0300-8126 | ||
| 024 | 7 |
_a10.1007/s150100050038 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPalmieri, F | |
| 245 | 0 | 0 |
_aNegative predictors of survival in HIV-infected patients with culture-confirmed pulmonary tuberculosis. _h[electronic resource] |
| 260 |
_bInfection _c |
||
| 300 |
_a331-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xdiagnosis |
| 650 | 0 | 4 |
_aAcquired Immunodeficiency Syndrome _ximmunology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibiotics, Antitubercular _xpharmacology |
| 650 | 0 | 4 |
_aAntitubercular Agents _xpharmacology |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aDrug Resistance, Microbial |
| 650 | 0 | 4 | _aDrug Resistance, Multiple |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xpharmacology |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMycobacterium tuberculosis _xdrug effects |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRifampin _xpharmacology |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xdiagnosis |
| 700 | 1 | _aPellicelli, A M | |
| 700 | 1 | _aGirardi, E | |
| 700 | 1 | _aDe Felici, A P | |
| 700 | 1 | _aDe Mori, P | |
| 700 | 1 | _aPetrosillo, N | |
| 700 | 1 | _aIppolito, G | |
| 773 | 0 |
_tInfection _gvol. 27 _gno. 6 _gp. 331-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s150100050038 _zAvailable from publisher's website |
| 999 |
_c10580111 _d10580111 |
||